KR102880762B1 - 티카그렐러 활성을 반전시키는 방법 - Google Patents

티카그렐러 활성을 반전시키는 방법

Info

Publication number
KR102880762B1
KR102880762B1 KR1020217011614A KR20217011614A KR102880762B1 KR 102880762 B1 KR102880762 B1 KR 102880762B1 KR 1020217011614 A KR1020217011614 A KR 1020217011614A KR 20217011614 A KR20217011614 A KR 20217011614A KR 102880762 B1 KR102880762 B1 KR 102880762B1
Authority
KR
South Korea
Prior art keywords
ser
ticagrelor
pharmaceutical composition
hours
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217011614A
Other languages
English (en)
Korean (ko)
Other versions
KR20210091698A (ko
Inventor
존 리
데이비드 제임스 발렌스
Original Assignee
에스에프제이 파마 엑스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69887913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102880762(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에스에프제이 파마 엑스, 인코포레이티드 filed Critical 에스에프제이 파마 엑스, 인코포레이티드
Priority to KR1020257035868A priority Critical patent/KR20250161038A/ko
Publication of KR20210091698A publication Critical patent/KR20210091698A/ko
Application granted granted Critical
Publication of KR102880762B1 publication Critical patent/KR102880762B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217011614A 2018-09-20 2019-09-20 티카그렐러 활성을 반전시키는 방법 Active KR102880762B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257035868A KR20250161038A (ko) 2018-09-20 2019-09-20 티카그렐러 활성을 반전시키는 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733892P 2018-09-20 2018-09-20
US62/733,892 2018-09-20
US201962806225P 2019-02-15 2019-02-15
US62/806,225 2019-02-15
US201962836373P 2019-04-19 2019-04-19
US62/836,373 2019-04-19
PCT/US2019/052173 WO2020061465A1 (en) 2018-09-20 2019-09-20 Methods of reversing ticagrelor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257035868A Division KR20250161038A (ko) 2018-09-20 2019-09-20 티카그렐러 활성을 반전시키는 방법

Publications (2)

Publication Number Publication Date
KR20210091698A KR20210091698A (ko) 2021-07-22
KR102880762B1 true KR102880762B1 (ko) 2025-11-03

Family

ID=69887913

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217011614A Active KR102880762B1 (ko) 2018-09-20 2019-09-20 티카그렐러 활성을 반전시키는 방법
KR1020257035868A Pending KR20250161038A (ko) 2018-09-20 2019-09-20 티카그렐러 활성을 반전시키는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257035868A Pending KR20250161038A (ko) 2018-09-20 2019-09-20 티카그렐러 활성을 반전시키는 방법

Country Status (12)

Country Link
EP (2) EP4653465A3 (https=)
JP (2) JP7478975B2 (https=)
KR (2) KR102880762B1 (https=)
CN (1) CN113194821B (https=)
AU (1) AU2019342755B2 (https=)
CA (1) CA3113654A1 (https=)
DK (1) DK3852617T3 (https=)
ES (1) ES3042247T3 (https=)
FI (1) FI3852617T3 (https=)
MX (1) MX2021003298A (https=)
PL (1) PL3852617T3 (https=)
WO (1) WO2020061465A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6799530B2 (ja) 2014-10-01 2020-12-16 メディミューン リミテッド チカグレロルに対する抗体および使用方法
KR102880762B1 (ko) * 2018-09-20 2025-11-03 에스에프제이 파마 엑스, 인코포레이티드 티카그렐러 활성을 반전시키는 방법
EP4337253A4 (en) * 2021-05-10 2025-03-19 Sfj Pharmaceuticals X, Ltd. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
KR102952285B1 (ko) 2021-07-13 2026-04-13 주식회사 엘지에너지솔루션 전지의 용접 상태 검사 방법
WO2026019858A1 (en) * 2024-07-16 2026-01-22 SFJ Pharma X, Inc. Methods of reversing ticagrelor activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160130366A1 (en) * 2014-10-01 2016-05-12 Medimmune Limited Antibodies to ticagrelor and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03154867A (ja) * 1989-11-13 1991-07-02 Teijin Ltd １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット
US9101642B2 (en) 2011-06-01 2015-08-11 Astrazeneca Ab Ticagrelor co-crystal
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用
WO2016033424A1 (en) * 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
AU2016210973B2 (en) * 2015-01-27 2019-02-14 Astrazeneca Ab Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
KR101916956B1 (ko) * 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
IL267519B2 (en) * 2016-12-23 2025-04-01 Novartis Ag Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
KR102880762B1 (ko) * 2018-09-20 2025-11-03 에스에프제이 파마 엑스, 인코포레이티드 티카그렐러 활성을 반전시키는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160130366A1 (en) * 2014-10-01 2016-05-12 Medimmune Limited Antibodies to ticagrelor and methods of use

Also Published As

Publication number Publication date
JP7478975B2 (ja) 2024-05-08
DK3852617T3 (da) 2025-10-20
FI3852617T3 (fi) 2025-10-21
JP2022501368A (ja) 2022-01-06
ES3042247T3 (en) 2025-11-19
US20210347915A1 (en) 2021-11-11
MX2021003298A (es) 2021-08-11
WO2020061465A1 (en) 2020-03-26
PL3852617T3 (pl) 2026-01-26
CN113194821B (zh) 2025-07-04
EP3852617B1 (en) 2025-09-10
CA3113654A1 (en) 2020-03-26
JP2024096134A (ja) 2024-07-12
KR20250161038A (ko) 2025-11-14
EP3852617A4 (en) 2022-08-24
KR20210091698A (ko) 2021-07-22
AU2019342755A1 (en) 2021-05-06
EP4653465A3 (en) 2026-01-07
AU2019342755B2 (en) 2025-12-11
EP4653465A2 (en) 2025-11-26
CN113194821A (zh) 2021-07-30
EP3852617A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
KR102880762B1 (ko) 티카그렐러 활성을 반전시키는 방법
KR20190044673A (ko) 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법
EP4488295A2 (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
JP2022501368A5 (https=)
JP2023138982A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法
US20230192895A1 (en) Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
CN120265653A (zh) 治疗心血管疾病的方法
JP2023507795A5 (https=)
AU2017355613B2 (en) Treatment regimens
US12617870B2 (en) Methods of reversing ticagrelor activity
Pickett et al. Prolonged Infusion of Eptifibatide as Bridge Therapy Between Bare‐Metal Stent Insertion and Cardiovascular Surgery: Case Report and Review of the Literature
US20140228316A1 (en) PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JP2023541249A (ja) 治療用抗体製剤
US20200055942A1 (en) Treatment regimens
US20260022197A1 (en) Methods of reversing ticagrelor activity
US20250018010A1 (en) Pharmaceutical composition
KR20210008847A (ko) 카나키누맙의 용도
WO2026072994A1 (en) Methods for the treatment of cardiovascular disease
AU2024349732A1 (en) Methods for the treatment of cardiovascular disease
HK40085254A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40058594A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)